Date: 2017-04-18
Type of information: Licensing agreement
Compound: up to three Generation 2+ antisense drugs
Company: Ionis Pharmaceuticals (USA - CA) Suzhou Ribo Life Science (China)
Therapeutic area: Cancer - Oncology - Metabolic diseases
Type agreement: collaboration - licensing - development - commercialisation
Action mechanism: antisense drug/si RNA/RNAi.
Disease:
Details:
- • On April 18, 2017, Ionis Pharmaceuticals announced a collaboration and license agreement with Suzhou Ribo Life Science (Ribo) to develop and commercialize RNA-targeted therapeutics in China. Ribo is devoted to the development of nucleic acid drugs and related products based on the RNA interference (RNAi) technology.
- Ionis granted Ribo a license for the right to commercialize in China two Ionis Generation 2+ antisense drugs in metabolic disease and cancer and an option to license a third pre-specified Generation 2+ antisense drug. In addition, Ribo will be responsible for conducting a multi-year research and drug discovery program to identify drugs that utilize Ionis' ssRNAi technology.
Financial terms:
- Ionis will receive an undisclosed up-front payment and equity in Ribo. Ionis retains the rights to develop and commercialize ssRNAi technology and all drugs under the collaboration outside of China.
- Following the identification of a development candidate, Ribo may exercise its option to license each drug by paying Ionis a license fee. For each drug that Ribo licenses, Ribo will be responsible for all development and commercialization
- Ribo will provide Ionis a royalty-free license to the data and intellectual property created under the collaboration.activities and costs in China. Ionis is eligible to receive development, regulatory and commercial milestone payments as each drug advances. In addition, Ionis is eligible to receive royalties on net sales of each drug.
Latest news:
Is general: Yes
